- Home
- SIEB vs IMAB Comparison
SIEB vs IMAB Comparison
Compare SIEB & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- IMAB
- Stock Information
- Founded
- SIEB 1886
- IMAB 2014
- Country
- SIEB United States
- IMAB United States
- Employees
- SIEB N/A
- IMAB N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SIEB Finance
- IMAB Health Care
- Exchange
- SIEB Nasdaq
- IMAB Nasdaq
- Market Cap
- SIEB 94.9M
- IMAB 83.8M
- IPO Year
- SIEB N/A
- IMAB 2020
- Fundamental
- Price
- SIEB $3.01
- IMAB $1.07
- Analyst Decision
- SIEB
- IMAB Strong Buy
- Analyst Count
- SIEB 0
- IMAB 3
- Target Price
- SIEB N/A
- IMAB $8.00
- AVG Volume (30 Days)
- SIEB 23.7K
- IMAB 682.1K
- Earning Date
- SIEB 11-12-2024
- IMAB 03-13-2025
- Dividend Yield
- SIEB N/A
- IMAB N/A
- EPS Growth
- SIEB 61.43
- IMAB N/A
- EPS
- SIEB 0.27
- IMAB N/A
- Revenue
- SIEB $83,357,000.00
- IMAB $3,313,984.00
- Revenue This Year
- SIEB N/A
- IMAB N/A
- Revenue Next Year
- SIEB N/A
- IMAB N/A
- P/E Ratio
- SIEB $11.18
- IMAB N/A
- Revenue Growth
- SIEB 27.81
- IMAB N/A
- 52 Week Low
- SIEB $1.41
- IMAB $0.84
- 52 Week High
- SIEB $3.34
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- SIEB 50.35
- IMAB 55.17
- Support Level
- SIEB $2.91
- IMAB $1.00
- Resistance Level
- SIEB $3.34
- IMAB $1.20
- Average True Range (ATR)
- SIEB 0.17
- IMAB 0.12
- MACD
- SIEB -0.03
- IMAB 0.02
- Stochastic Oscillator
- SIEB 43.10
- IMAB 40.97
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).